22 min listen
Robert Busch, MD: Topline Results of EMPEROR-REDUCED
FromDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Robert Busch, MD: Topline Results of EMPEROR-REDUCED
FromDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
ratings:
Length:
17 minutes
Released:
Jul 31, 2020
Format:
Podcast episode
Description
In this episode we will be discussing reaction to topline results from the EMPEROR-REDUCED trial examining the use of empagliflozin for heart failure in patients with and without diabetes with endocrinologist Dr. Robert Busch.
Announced on July 30, by Berringer Ingelheim and Lilly,topline results indicate use of empagliflozin was associated with a decrease in the composite endpoint of CV death and worsening heart failure. Scheduled to be presented at ESC 2020, the results will be presented 1 year after the results of DAPA-HF.
Now, results of EMPEROR-REDUCED have a chance to firmly cement the notion that the benefit on heart failure proven in clinical trials with dapagliflzoin and potentially empaglfilziin is truly a class effect of SGLT2s.
Announced on July 30, by Berringer Ingelheim and Lilly,topline results indicate use of empagliflozin was associated with a decrease in the composite endpoint of CV death and worsening heart failure. Scheduled to be presented at ESC 2020, the results will be presented 1 year after the results of DAPA-HF.
Now, results of EMPEROR-REDUCED have a chance to firmly cement the notion that the benefit on heart failure proven in clinical trials with dapagliflzoin and potentially empaglfilziin is truly a class effect of SGLT2s.
Released:
Jul 31, 2020
Format:
Podcast episode
Titles in the series (94)
Diabetes Research & COVID-19 by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives